The predominant excitatory transmitter in the mammalian central nervous system. Acts at ionotropic and metabotropic glutamate receptors. MNI-caged-L-glutamate (Cat. No. 1490) and D-Glutamic acid (Cat. No. 0217) are also available.
|Storage||Store at RT|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
|Solubility||Soluble to 100 mM in 1eq. NaOH|
Preparing Stock Solutions
The following data is based on the product molecular weight 147.13. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||6.8 mL||33.98 mL||67.97 mL|
|5 mM||1.36 mL||6.8 mL||13.59 mL|
|10 mM||0.68 mL||3.4 mL||6.8 mL|
|50 mM||0.14 mL||0.68 mL||1.36 mL|
The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.
References are publications that support the products' biological activity.
Monaghan et al (1989) The excitatory amino acid receptors: their classes, pharmacology and distinct properties in the function of the central nervous system. Annu.Rev.Pharmacol.Toxicol. 29 365 PMID: 2543272
Watkins and Evans (1981) Excitatory amino acid transmitters. Annu.Rev.Pharmacol.Toxicol. 21 165 PMID: 6112965
If you know of a relevant reference for L-Glutamic acid, please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: L-Glutamic acid, supplier, Endogenous, non-selective, agonists, Glutamate, Ionotropic, Non-Selective, iGluR, Receptors, mGlur, Metabotropic, Non-selective, mGlu, Tocris Bioscience
7 Citations for L-Glutamic acid
Citations are publications that use Tocris products. Selected citations for L-Glutamic acid include:
Schitine et al (2015) Functional plasticity of GAT-3 in avian Müller cells is regulated by neurons via a glutamatergic input. J Neurosci 82 42 PMID: 25700791
Owaisat et al (2012) In vivo comparison of harmine efficacy against psychostimulants: preferential inhibition of the cocaine response through a glutamatergic mechanism. Neurosci Lett 525 12 PMID: 22877698
Tallarida et al (2012) Glutamate carboxypeptidase II (GCPII) inhibitor displays anti-glutamate and anti-cocaine effects in an invertebrate assay. Amino Acids 42 2521 PMID: 21850438
Moreno et al (2012) Identification of three residues essential for 5-hydroxytryptamine 2A-metabotropic glutamate 2 (5-HT2A·mGlu2) receptor heteromerization and its psychoactive behavioral function. J Biol Chem 287 44301 PMID: 23129762
Moreno et al (2011) Maternal influenza viral infection causes schizophrenia-like alterations of 5-HT2A and mGlu2 receptors in the adult offspring. J Neurosci 31 1863 PMID: 21289196
Galici et al (2006) Biphenyl-indanone A, a positive allosteric modulator of the metabotropic glutamate receptor subtype 2, has antipsychotic- and anxiolytic-like effects in mice. J Pharmacol Exp Ther 318 173 PMID: 16608916
Calò et al (2005) Interactions between ephrin-B and metabotropic glutamate 1 receptors in brain tissue and cultured neurons. J Neurosci 25 2245 PMID: 15745950
Do you know of a great paper that uses L-Glutamic acid from Tocris? If so please let us know.
Literature in this Area
Learning & Memory Poster
Recognition memory enables us to make judgements about whether or not we have encountered a particular stimulus before. This poster outlines the cellular mechanisms underlying recognition memory and its links to long-term depression, as well as the use of pharmacological intervention to assess the role of neurotransmitters in recognition memory.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.